Clinical Trials
7
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:5
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (83.3%)Phase 3
1 (16.7%)Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients with Bietti Crystalline Dystrophy
Phase 3
Not yet recruiting
- Conditions
- Bietti Crystalline DystrophyInherited Retinal Diseases
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT06699108
- Locations
- 🇨🇳
Shanghai Vitalgen Biopharma Co.,Ltd., Shanghai, Shanghai, China
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT06480461
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency
Phase 1
Not yet recruiting
- Conditions
- Aromatic L-amino Acid Decarboxylase Deficiency
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06432140
A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b
Phase 1
Recruiting
- Conditions
- Glutaric Aciduria Type IGlutaric Acidemia Type I
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06217861
- Locations
- 🇨🇳
The Children's Hospital Zhejiang University Shcool of Medicine, Hangzhou, Zhejiang, China
Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy
Phase 1
Not yet recruiting
- Conditions
- Bietti Crystalline Dystrophy
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05694598
- Locations
- 🇨🇳
Shanghai Vitalgen Biopharma Co.,Ltd., Shanghai, Shanghai, China
- Prev
- 1
- 2
- Next
News
Shanghai Vitalgen Advances VGR-R01 Gene Therapy to Phase 3 Trial for Bietti Crystalline Dystrophy
Shanghai Vitalgen BioPharma has initiated a Phase 3 multicenter randomized controlled trial evaluating VGR-R01 gene therapy in 45 patients with Bietti crystalline dystrophy.